How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

124,661 results for

Review of Systems

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review

Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

202. Effect of systemic steroids on post-tonsillectomy bleeding and reinterventions: systematic review and meta-analysis of randomised controlled trials

Effect of systemic steroids on post-tonsillectomy bleeding and reinterventions: systematic review and meta-analysis of randomised controlled trials Effect of systemic steroids on post-tonsillectomy bleeding and reinterventions: systematic review and meta-analysis of randomised controlled trials Effect of systemic steroids on post-tonsillectomy bleeding and reinterventions: systematic review and meta-analysis of randomised controlled trials Plante J, Turgeon AF, Zarychanski R, Lauzier F (...) ' objectives To evaluate the risk of postoperative bleeding and reintervention with the use of systemic steroids in patients undergoing tonsillectomy. Searching Eight databases (including MEDLINE, EMBASE and The Cochrane Library) were searched to March, 2011; Google Scholar and Intute search engines were also accessed. Search terms were reported. No language restrictions were applied. References of included studies and relevant reviews identified through the searches were scanned to locate further studies

2012 DARE.

203. Effect of perioperative systemic alpha-2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials

Effect of perioperative systemic alpha-2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

204. Effect of clinical decision-support systems: a systematic review

Effect of clinical decision-support systems: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

205. Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review

Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

206. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

207. Ethnographic methods for researching acute healthcare encounters: a systemic review (the EMERALd review)

Ethnographic methods for researching acute healthcare encounters: a systemic review (the EMERALd review) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary

2019 PROSPERO

208. An adapted systematic review of the effectiveness of electronic nicotine delivery systems (ENDS) for smoking cessation a review of randomised control trials and prospective cohort studies

An adapted systematic review of the effectiveness of electronic nicotine delivery systems (ENDS) for smoking cessation a review of randomised control trials and prospective cohort studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility (...) (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we

2019 PROSPERO

209. Topical and systemic antifungal therapy for chronic rhinosinusitis. Full Text available with Trip Pro

Topical and systemic antifungal therapy for chronic rhinosinusitis. This review adds to a series of reviews looking at primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common and characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal blockage, nasal discharge, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps. Antifungals have been suggested (...) as a treatment for chronic rhinosinusitis.To assess the effects of systemic and topical antifungal agents in patients with chronic rhinosinusitis, including those with allergic fungal rhinosinusitis (AFRS) and, if possible, AFRS exclusively.The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished

2018 Cochrane

210. Systemic vasculitis

Systemic vasculitis Systemic vasculitis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Systemic vasculitis Last reviewed: February 2019 Last updated: April 2018 Summary The systemic vasculitides are sub-acute illnesses associated with signs and symptoms of chronic inflammation. Vasculitis can affect virtually any organ system; many of these diseases have typical patterns of involvement that are recognisable (...) by experienced clinicians. The diagnostic value of a biopsy, performed early in the course of illness, cannot be overstated. Drugs used to treat vasculitis depend on the severity of the clinical manifestations. Definition In its strictest sense, the term vasculitis denotes inflammation of a blood vessel, which is characterised by the presence of an inflammatory infiltrate and destruction of the vessel wall. Commonly, however, vasculitis refers to the systemic vasculitides, which are autoimmune disorders

2018 BMJ Best Practice

211. Limited cutaneous systemic sclerosis

Limited cutaneous systemic sclerosis Limited cutaneous systemic sclerosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Limited cutaneous systemic sclerosis Last reviewed: February 2019 Last updated: November 2018 Summary A type of systemic sclerosis characterised by skin fibrosis of the fingers (sclerodactyly) and, in some cases, of the face and neck or the skin distal to the elbows and/or knees. It does (...) not affect the upper arms, upper legs, or trunk. Previously known as CREST syndrome, which stands for the presence of calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, and telangiectasia. This term is rarely used now as CREST features are not limited to this type of systemic sclerosis. Presence of anti-centromere antibody implies better prognosis and longer survival. Treatment is targeted to symptoms, or to organs involved, and to influence the fibrosis of the skin and other

2018 BMJ Best Practice

212. Systemic lupus erythematosus

Systemic lupus erythematosus Systemic lupus erythematosus - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Systemic lupus erythematosus Last reviewed: February 2019 Last updated: August 2018 Summary Generalised disorder that can affect any system. Symptoms and signs may accumulate over time. The diagnosis is made using criteria recommended by the American College of Rheumatology. Treatments for mild to moderate (...) serositis or arthritis include hydroxychloroquine, non-steroidal anti-inflammatory drugs, or corticosteroids. Treatments for more severe disease may include cyclophosphamide, mycophenolate, or tacrolimus plus corticosteroids. Definition Systemic lupus erythematosus (SLE) is a chronic multi-system disorder that most commonly affects women during their reproductive years. It is characterised by the presence of antinuclear antibodies. In addition to constitutional symptoms, it most frequently involves

2018 BMJ Best Practice

213. Systemic sclerosis (scleroderma)

Systemic sclerosis (scleroderma) Systemic sclerosis (scleroderma) - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Systemic sclerosis (scleroderma) Last reviewed: February 2019 Last updated: March 2018 Summary A non-contagious, chronic, multi-system disease. Initial symptoms are non-specific and include fatigue, vague musculoskeletal complaints, diffuse swelling of hands, and Raynaud's phenomenon. Aetiology (...) and pathogenesis are unknown. Disease course is variable, but the condition rarely subsides spontaneously. There are two main subtypes of systemic sclerosis (SSc): limited cutaneous SSc and diffuse cutaneous SSc. The limited cutaneous form tends to have less severe internal organ involvement and a better prognosis, but these subjects still need to be followed closely for possible complications. Clinical course is determined by extent of vascular and fibrosing complications. Vascular involvement includes

2018 BMJ Best Practice

214. Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus

Institute, Ottawa, Ontario. These guidelines were supported by a peer-reviewed dissemination event grant from the Canadian Institutes of Health Research, a meeting grant from the Arthritis Society of Canada, and support from the Canadian Rheumatology Association and Lupus Canada. Dr. Clarke holds The Arthritis Society Chair in Rheumatic Diseases at the Cumming School of of Rheumatology The Journal on March 26, 2019 - Published by www.jrheum.org Downloaded from Systemic lupus erythematosus (SLE (...) Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus The Journal of Rheumatology and Monitoring of Systemic Lupus Erythematosus Canadian Rheumatology Association Recommendations for the Assessment Touma, Evelyne Vinet and Nancy Santesso Reynolds, Earl Silverman, Konstantinos Tselios, Manon Suitner, Murray Urowitz, Zahi Jordi Pardo Pardi, Christine Peschken, Christian Pineau, Janet Pope, Tamara Rader, Jen Legault, Deborah Levy, Lily

2018 CPG Infobase

215. WITHDRAWN: Nursing record systems: effects on nursing practice and healthcare outcomes. Full Text available with Trip Pro

WITHDRAWN: Nursing record systems: effects on nursing practice and healthcare outcomes. A nursing record system is the record of care that was planned or given to individual patients and clients by qualified nurses or other caregivers under the direction of a qualified nurse. Nursing record systems may be an effective way of influencing nurse practice.To assess the effects of nursing record systems on nursing practice and patient outcomes.For the original version of this review in 2000 (...) related reviews.Randomised controlled trials (RCTs), controlled before and after studies, and interrupted time series comparing one kind of nursing record system with another in hospital, community or primary care settings. The participants were qualified nurses, students or healthcare assistants working under the direction of a qualified nurse, and patients receiving care recorded or planned using nursing record systems.Two review authors (in two pairs) independently assessed trial quality

2018 Cochrane

216. WITHDRAWN: Systemic treatments for metastatic cutaneous melanoma. Full Text available with Trip Pro

WITHDRAWN: Systemic treatments for metastatic cutaneous melanoma. Systemic therapies for metastatic cutaneous melanoma, the most aggressive of all skin cancers, remain disappointing. Few lasting remissions are achieved and the therapeutic aim remains one of palliation.Many agents are used alone or in combination with varying degrees of toxicity and cost. It is unclear whether evidence exists to support these complex regimens over best supportive care / placebo.To review the benefits from (...) with histologically proven metastatic cutaneous melanoma in which systemic anti-cancer therapy was compared with placebo or supportive care.Study selection was performed by two independent reviewers. Data extraction forms were used for studies which appeared to meet the selection criteria and, where appropriate, full text articles were retrieved and reviewed independently.No randomised controlled trials were found comparing a systemic therapy with placebo or best supportive care in metastatic cutaneous

2018 Cochrane

217. Systemic candidiasis

Systemic candidiasis Systemic candidiasis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Systemic candidiasis Last reviewed: February 2019 Last updated: November 2018 Summary Major risk factors are use of central venous catheters, exposure to broad-spectrum antibiotics, and neutropenia. Blood cultures are only 70% to 80% sensitive in diagnosis. Treatment should be started within 24 hours of diagnosis to improve (...) outcome. Echinocandins or fluconazole are first-line choices. Central venous catheters should be removed in non-neutropenic patients. Ophthalmological examination is required in all patients with candidaemia. Definition Systemic candidiasis (acute disseminated candidiasis) is an infection of blood or other normally sterile sites (e.g., pleural and peritoneal fluid) with Candida species, usually in association with fever, hypotension, and/or leukocytosis. Candida organisms may be disseminated

2018 BMJ Best Practice

218. Limited cutaneous systemic sclerosis

Limited cutaneous systemic sclerosis Limited cutaneous systemic sclerosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Limited cutaneous systemic sclerosis Last reviewed: February 2019 Last updated: November 2018 Summary A type of systemic sclerosis characterised by skin fibrosis of the fingers (sclerodactyly) and, in some cases, of the face and neck or the skin distal to the elbows and/or knees. It does (...) not affect the upper arms, upper legs, or trunk. Previously known as CREST syndrome, which stands for the presence of calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, and telangiectasia. This term is rarely used now as CREST features are not limited to this type of systemic sclerosis. Presence of anti-centromere antibody implies better prognosis and longer survival. Treatment is targeted to symptoms, or to organs involved, and to influence the fibrosis of the skin and other

2018 BMJ Best Practice

219. Systemic corticosteroids for acute otitis media in children. Full Text available with Trip Pro

Organization (WHO) International Clinical Trials Registry Platform (ICTRP) for completed and ongoing studies, to 20 February 2018. We checked the reference lists of all primary studies and review articles for additional references and contacted experts in the field to identify additional unpublished materials.We included randomised controlled trials of children with AOM that compared any systemic corticosteroid (oral or parenteral) with placebo, either with antibiotics (corticosteroid plus antibiotic (...) Systemic corticosteroids for acute otitis media in children. Acute otitis media (AOM) is a common acute infection in children. Pain is its most prominent and distressing symptom. Antibiotics are commonly prescribed for AOM, although they have only a modest effect in reducing pain at two to three days. There is insufficient evidence for benefits of other treatment options, including systemic corticosteroids. However, systemic corticosteroids are potent anti-inflammatory drugs, and so

2018 Cochrane

220. Skin involvement in systemic sclerosis: rituximab

on dosage regimens for the licensed indications can be found in the summary of product characteristics. Skin involvement in systemic sclerosis: rituximab (ES7) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 6 of 63Dosing information for rituximab for systemic sclerosis (an off-label indication) is discussed in the evidence review within this evidence summary. Cost Rituximab 10 mg/ml concentrate for solution (...) participants Phumethum V, Jamal S and Johnson SR (2011) Biologic therapy for systemic sclerosis: a systematic review. The Journal of Rheumatology 38: 289–96 No meta- analyses Provides no additional evidence Smith V, Van Praet JT, Vandooren B et al. (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Annals of the Rheumatic Diseases 69: 193–7 Non- comparative study including less than 10 participants Skin involvement in systemic sclerosis: rituximab

2017 National Institute for Health and Clinical Excellence - Advice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>